Table 3.
Transplant characteristics
| Characteristic | Total | Skin only | Systemic only without skin | Skin and systemic | P |
|---|---|---|---|---|---|
| N | 25 | 5 | 5 | 15 | |
| Time from Dx to transplant, median (range), d | 182 (101, 335) | 189 (101, 271) | 156 (119, 169) | 189 (122, 335) | .091 |
| Time from Trt1 to transplant, median (range), d | 131 (72, 280) | 98 (72, 189) | 117 (108, 149) | 173 (72, 280) | .30 |
| Stage at transplant: CR | 25 (100) | 5 (100) | 5 (100) | 15 (100) | — |
| Type of transplant | |||||
| Autologous | 5 (20) | 3 (60) | 0 (0) | 2 (13) | .075 |
| Allogeneic | 20 (80) | 2 (40) | 5 (100) | 13 (87) | |
| Cell source | |||||
| Peripheral blood | 23 (92) | 5 (100) | 5 (100) | 13 (87) | — |
| Cord blood | 2 (8) | 0 (0) | 0 (0) | 2 (13) | |
| Donor type | |||||
| Autologous | 5 (20) | 3 (60) | 0 (0) | 2 (13) | — |
| MRD | 7 (28) | 0 (0) | 2 (40) | 5 (33) | |
| MURD | 5 (20) | 1 (20) | 1 (20) | 3 (20) | |
| MMURD | 6 (24) | 1 (20) | 2 (40) | 3 (20) | |
| Haploidentical | 1 (4) | 0 (0) | 0 (0) | 1 (7) | |
| Umbilical cord blood | 1 (4) | 0 (0) | 0 (0) | 1 (7) | |
| Conditioning regimen | |||||
| BEAM ± alemtuzumab | 4 (16) | 2 (40) | 0 (0) | 2 (13) | — |
| Bu/Cy | 1 (4) | 0 (0) | 0 (0) | 1 (7) | |
| Bu/Flu ± other | 5 (20) | 2 (40) | 0 (0) | 3 (20) | |
| CBV | 1 (4) | 0 (0) | 0 (0) | 1 (7) | |
| Clofarabine ± other | 3 (12) | 0 (0) | 1 (20) | 2 (13) | |
| Cy/Flu ± other | 4 (16) | 0 (0) | 1 (20) | 3 (20) | |
| Cy ± other | 3 (12) | 1 (20) | 1 (20) | 1 (7) | |
| Flu/Mel ± other | 4 (16) | 0 (0) | 2 (40) | 2 (13) | |
| GVHD prophylaxis | |||||
| Cyclo/MMF | 3 (12) | 0 (0) | 1 (20) | 2 (13) | — |
| TCD | 3 (12) | 0 (0) | 1 (20) | 2 (13) | |
| TBI/ATG | 1 (3) | 0 (0) | 0 (0) | 1 (7) | |
| Tac ± MMF or + Siro/MMF | 3 (10) | 0 (0) | 0 (0) | 3 (20) | |
| Tac/MTX | 4 (16) | 1 (20) | 2 (40) | 1 (7) | |
| Tac/MTX/Bort | 1 (3) | 0 (0) | 0 (0) | 1 (7) | |
| Tac/MTX/Siro | 4 (16) | 1 (20) | 1 (20) | 2 (13) | |
| Autologous/none | 5 (20) | 3 (60) | 0 (0) | 2 (13) | |
| Unknown | 1 (3) | 0 (0) | 0 (0) | 1 (7) |
BEAM, carmustine, etoposide, cytarabine, melphalan; Bu/Cy, busulfan, cyclophosphamide; Bu/Flu, busulfan, fludarabine; CBV, cyclophosphamide, carmustine, etoposide; CR, complete remission; Cy, cyclophosphamide; Cy/Flu, cyclophosphamide, fludarabine; Cyclo/MMF, cyclosporine, mycophenolate mofetil; Dx, diagnosis; Flu/Mel, fludarabine, melphalan; MMURD, mismatched unrelated donor; MRD, matched, related donor; MURD, matched, unrelated donor; Siro, sirolimus; Siro/MMF, sirolimus, mycophenolate mofetil; Tac ± MMF, tacrolimus ± mycophenolate mofetil; Tac/MTX, tacrolimus, methotrexate; Tac/MTX/Bort, tacrolimus, methotrexate, bortezomib; Tac/MTX/Siro, tacrolimus, methotrexate, sirolimus; TBI/ATG, total body irradiation, antithymocyte globulin; TCD, T-cell depletion; Trt1, first-line therapy.